• Explore /
  • Poster
  • / STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).

STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).

Abstract Video & Slides Poster

Authors

null

J. Randolph Hecht

David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Santa Monica, CA;

J. Randolph Hecht , Josep Tabernero , Aparna Raj Parikh , Yijia Wang , Zhong Wang , Martin Schwickart , Dominic Curran , Anwaar Saeed

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05425940

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS267)

DOI

10.1200/JCO.2023.41.4_suppl.TPS267

Abstract #

TPS267

Poster Bd #

P9

Abstract Disclosures

Similar Posters

First Author: Anwaar Saeed

First Author: Neeraj Agarwal

First Author: Toni K. Choueiri

First Author: Inkeun Park